Lupin Shares Rise on USFDA Approval for Raltegravir Tablets

On May 8, 2025, Lupin’s share price gained after receiving USFDA approval for Raltegravir tablets. As the exclusive first-to-file for this product,

n is eligible for 180 days of generic drug exclusivity. The tablets will be manufactured at Lupin’s Nagpur facility in India.